Colorectal Cancer Clinical Trials in Atlanta

Showing 1-20 of 328 trials

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

NCT05514717

A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.

HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Non-Small Cell Lung Cancer+3 more

Day One Biopharmaceuticals, Inc.57 participantsStarted Jan 2023

Los Angeles, California, United States • Los Angeles, California, United States • Stanford, California, United States +11 more locations

Active Not RecruitingPhase 3< 1 mile

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Advanced Colorectal CancerMetastatic Colorectal Cancer

Mirati Therapeutics Inc.461 participantsStarted Jul 2021

Alabaster, Alabama, United States • Bessemer, Alabama, United States • Birmingham, Alabama, United States +416 more locations

A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Colorectal Cancer Trials in Other Cities

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)

FOG-001 in Locally Advanced or Metastatic Solid Tumors

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)

Assessing How Normal Variations in CT Scanning Affects Its Interpretation

A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer

Early Detection of Advanced Adenomas and Colorectal Cancer

Other Conditions in Atlanta